Novartis to Acquire Avidity Biosciences
Novartis will buy Avidity Biosciences for US$12 billion, gaining its RNA-based therapeutic platform and rare-disease programmes.
The transaction gives Novartis full ownership of Avidity’s RNA-based antibody-oligonucleotide conjugate platform and three advanced programmes targeting neuromuscular disorders, including:
- Duchenne muscular dystrophy
- Myotonic dystrophy type 1
- Facioscapulohumeral muscular dystrophy
The purchase underscores Novartis’s strategy to expand into rare and genetic diseases as it faces increasing competition for some of its established medicines.
Avidity’s innovative platform enables precise delivery of RNA therapeutics to muscle tissue, a capability that has generated strong industry interest.
Author's summary: Novartis acquires Avidity Biosciences for $12 billion.
More News
- Sudan: North Darfur capital falls to RSF as UN warns of 'atrocities and mass displacement'
- The Angel Ball Honors Tina Knowles
- Al Nassr Al-Ittihad Jeddah 28 10 2025 Live Score and Match Summary
- From WNBA Court To Playmate Glam: Check Out Kysre Gondrezick’s Sexiest Photos
- Trump administration quietly purges ICE leaders in five cities, including Denver: Sources
- The Most Dazzling Looks From The Angel Ball's 2025 Red Carpet
- Al-Nassr 1-2 Al-Ittihad: Report, result and goals as Karim Benzema scores to knock Cristiano Ronaldo's side out of Kings Cup
- Atalanta v AC Milan: Confirmed line-ups as Rossoneri look to end hosts' unbeaten start
- Eintracht Frankfurt Borussia Dortmund 28 10 2025 Live Score and Match Summary
- Charlie Kirk’s accused killer allowed to wear street clothes in court